21/04/2017 12:30:00

Repligen to Report First Quarter 2017 Financial Results

WALTHAM, Mass., April 21, 2017 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report first quarter of 2017 financial results on Thursday, May 4, 2017. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EDT to discuss business updates and financial results for the reporting periods ended March 31, 2017. 

The conference call will be accessible by dialing toll-free (844) 835-7432 for domestic callers and (404) 537-3372 for international callers. Dial-in participants must provide the passcode 11424546. In addition, a webcast will be accessible via the Investor Relations section of the Company's website. Both the conference call and webcast will be archived for a period of time following the live event. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Replay listeners must provide the passcode 11424546. 

About Repligen Corporation

Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the interconnected phases of the biological drug manufacturing process. Our portfolio includes protein products (Protein A affinity ligands, cell culture growth factors), chromatography products (OPUS® pre-packed columns, chromatography resins, ELISA kits) and filtration products (XCell™ ATF Systems, TangenX™ Sius™ TFF cassettes). Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. The Protein A ligands and growth factor products that we manufacture are components of chromatography resins and cell culture media, respectively. We are the leading manufacturer of Protein A ligands, a critical component of Protein A resins that are the industry standard for downstream separation and purification of monoclonal antibody-based therapeutics. Our growth factors are used in upstream processes to accelerate cell growth and productivity. Our innovative line of OPUS® chromatography columns, used in downstream processes for bench-scale through clinical-scale purification needs, are delivered pre-packed with our customers' choice of resin and bed height. Our XCell™ ATF Systems, available in stainless steel and single-use configurations, continuously eliminate waste from a bioreactor to concentrate cells and increase productivity in upstream processes. Single-use Sius™ TFF cassettes and hardware are used for biologic drug concentration in downstream processes. Repligen's corporate headquarters are in Waltham, MA (USA) and our manufacturing facilities are located in Waltham, MA, Shrewsbury, MA, Lund, Sweden and Weingarten, Germany. 

This press release may contain forward-looking statements within the meaning of the federal securities laws. Investors are cautioned that statements in this press release which are not strictly historical statements including, without limitation, statements identified by words like "believe," "expect," "may," "will," "should," "seek," or "could" and similar expressions, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including risks discussed from time to time in our filings with the Securities and Exchange Commission. We expressly disclaim any responsibility to update any forward-looking statements, except as required by law.

Contact:

Sondra Newman

Senior Director Investor Relations

(781) 419-1881

snewman@repligen.com

Primary Logo

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
20 Oct
VWS
Der er for tiden en del debat omkring øget prispres på vindmøllemarkedet - bl.a. som følge af at Sie..
78
20 Oct
PNDORA
  Jeg har gentagne gange analyseret Pandora. Læsere, som ønsker min analyse af Pandoras forretningsm..
59
18 Oct
EI
Til direktionen.     Se så at få fyret den uduelige person, som I har ansat som moderator. Vedkommen..
43
18 Oct
NOVO-B
The FDA's Endocrinologic and Metabolic Drugs Advisory Committee votes 16 - 0 in favor of approval fo..
21
20 Oct
TEVA
Jeg deler spekulationerne omkring Kåres tiltrædelse dvs. den dårlige nyhedsstrøm er snart slut. Min ..
19
18 Oct
EI
Og til Moderator:     Du UNDERSTÅR dig i at fjerne dette indlæg uden at have forelagt det direktione..
17
18 Oct
PNDORA
Markedsværdi = DKK 64 milliarder   Pandora ejer 2,30 % af aktierne (som vi må antage ikke kommer i o..
14
16 Oct
OMXC25
Jeg har fuldstændig mistet enhver form for respekt for EU.   EU er i den grad blevet til en taberfor..
14
20 Oct
PNDORA
lugte af noget personligt mod alfinvest, vil jeg nu tillade mig at drage tvivl, både ved hans hensig..
13
20 Oct
PNDORA
Vanvittigt godt formuleret Peter. Det er næsten som at tage på universitetet og studere grønlandsk a..
13

Alliance Trust PLC : Net Asset Value(s)

23/10/2017 13:14:06
ALLIANCE TRUST PLC                                    At the close of business on Friday 20 October 2017: The Company's NAV per ordinary share, valued on a bid price basis with Debt at Par, was -       excluding income, 778.5p -       including income, 787.1p  The Company's NAV per ordinary share, valued on a bid price basis with Debt at Fair Value, was -       excluding inco..

Rathbones : Form 8.3 - [Clinigen Group PLC]

23/10/2017 10:58:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: Rathbone Brothers PLC (b) Owner or controller of ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
H.B. Fuller Poised for Global Growth with Acquisition of Royal Adhesives & Sealants
2
Sequent Announces Two New Sequent Platform Versions
3
Simmons Reports Third Quarter 2017 Earnings
4
Novartis combination adjuvant therapy Tafinlar® + Mekinist® receives FDA Breakthrough Therapy Designation for stage III BRAF V600 mutation-positive melanoma patients
5
MEDIA ADVISORY: US Commerce Secretary Wilbur Ross to Hold Listening Session at National Minority Supplier Development Council Annual Conference

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2017   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 October 2017 18:08:05
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20171023.1 - EUROWEB7 - 2017-10-23 19:08:05 - 2017-10-23 18:08:05 - 1000 - Website: OKAY